FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
Ralf‐Dieter Hofheinz(University of Mannheim), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Maria Loose(Krankenhaus Nordwest), Claudia Pauligk(Goethe University Frankfurt), Nils Homann(Fraunhofer Project Centre Wolfsburg), Eray Goekkurt(Sorbonne Université), Christoph Springfeld(Heidelberg University), Georg Martin Haag(Heidelberg University), Daniel Pink(Universitätsmedizin Greifswald), Wolf O. Bechstein(Unknown), Rolf Mahlberg(Klinikum Mutterhaus der Borromäerinnen), H. Zwenneke Flach(Viaa Christian University of Applied Sciences), Peter Reichardt(Helios Hospital Berlin-Buch), Kirsten Merx(Heidelberg University), Disorn Sookthai(Institute of Clinical Cancer Research), Thomas J. Ettrich(Universität Ulm), K Borchert(University Hospital Magdeburg), Gabriele Margareta Siegler(Nuremberg Hospital), Thorsten Oliver Goetze(Institute of Clinical Cancer Research), A. Battmann, Fuat Oduncu(LMU Klinikum), Matthias P. Ebert(Heidelberg University), Christian Teschendorf(St. Josefs Hospital), Albrecht Kretzschmar(Roche (Switzerland)), Timo Gaiser(University of Mannheim)
Cited by 97
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k